Clinical use of hematopoietic growth factors

Current Opinion in Oncology

Volumn 8, Issue 4, 1996, Pages 265-269

  Ganser, Arnold ^a   Karthaus, Meinolf ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THROMBOPOIETIN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029783776     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199607000-00001     Document Type: Review

References (28)

1. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994, 12:2471-2508.
2. Vose JM, Armitage JO: Clinical applications of hematopoietic growth factors. J Clin Oncol 1995, 13:1023-1035.
3. Gerhartz HH, Engelhard M, Meusers P, Britttinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, et al.: Randomized, double-blind, placebo-controlled, phase III study of recombinant human GM-CSF as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993, 82:2329-2339.
4. Woll PJ, Hodgetts J, Lomax I, et al.: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomised controlled trial of G-CSF in small-cell lung cancer. J Clin Oncol 1995, 13:652-659.
5. Steward WP, von Pawel J, Gatzemeier U, Thatcher N, Fritsch J: Dose intensification of VICE chemotherapy with GM-CSF in small cell lung cancer: a prospective randomized study of 301 patients. Eur J Cancer 1995, 31 a(suppl 5):18.
6. O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L, et al.: A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophos-phamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncol 1994, 5:709-716.
7. Logothethis CJ, Finn LD, Smith TS, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ: Escalated MVAC with or without recombinant human granulocyte-macrophage colony stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995, 13:2272-2277.
8. Chi KW, Chen CH, Chan WK, Chow KC, Chen SY, Yen SH, Chao JY, Chang CY, Chen KY: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995, 13:2620-2628
9. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994, 121:492-501.
10. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes P, Colomer R, Lopez-Brea M, Lopez E, Paz-Ares L, Hitt R, Garcia-Ribas I, Cuebo R, Alonso S, Cortes-Funes H: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995, 87:803-808.
11. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber Ch, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, Nicolay U, Gaus W, Heimpel H: GM-CSF in a double-blind randomized placebo-controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Leukemia 1995, 9:3-9.
12. Rowe JM, Andersen J, Mazza J, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E 1490). Blood 1995, 86:457-462.
13. Stone R, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer C: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677.
14. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzenneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1683.
15. Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasly K, Upchurch C, Livingston R: Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995, 13:1632-1641. This study had to be stopped early because of the development of prolonged cytopenia in patients treated concomitantly with GM-CSF and thoracic irradiation. The mechanism is unknown but probably due to the fact that a large proportion of the circulating progenitor cells that are mobilized during the regenerative phase after chemotherapy are irradiated during their passage through the heart and large mediastinal vessels.
16. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, Wandt H, Koch P, Kolbe K, Heyll A, Bentz M, Peters S, Diedrich R, Delhling J, Meyer P, Nowrousian MR, Löffler B, Weiss A, Kneba M, Fôller A, Graf M, Hecht T: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a phase III trial. Blood 1995, 86:444-450. This study demonstrates that concomitant administration of chemotherapy and G-CSF is possible without development of prolonged cytopenia.
17. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS: Granulocyte-colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective randomized trial. J Clin Oncol 1995, 13:1323-1327
18. Schmitz N, Linch DC, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HMS, Link H, Zander A, Barge A, Borkett K: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
19. Chatta GS, Price TH, Allen RC, Dale DC: Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly volunteers. Blood 1994, 84:2923-2929.
20. Bezwoda WR, Seymour L, Dansey KD: High-dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995, 13:2483-2489. High-dose chemotherapy used as a first-line regimen significantly improves response rate and overall survival compared with conventional chemotherapy.
21. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995, 333:283-287. Ex vivo culture and preservation of hematopoietic potential of autologous peripheral blood progenitor cells is possible according to these data and will allow further manipulation of the graft. The amount of tumor cell contamination might be reduced by ex vivo expansion techniques.
22. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and cancer-related anemia: results of double blind and open label follow-up studies. Semin Oncol 1994, 21(suppl 3):21-28.
23. Henry DH, Abels RI: Benefits of epoetin alfa in anemic cancer patients receiving chemotherapy. J Clin Oncol 1995, 13:2473-2474.
24. Campos E, Radford J, Steward W, Milroy R, Dougal M, Swindell R, Testa N, Thatcher N: Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995, 13:1623-1631.
25. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler, Essers U, Greil R, Grossi A, Jaeger G, LeMevel A, Najmann A, Silingardi V, Spriano M, van Hoof A, Ehmer B: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1993, 86:4446-4453.
26. Link H, Boogarts MA, Fauser AA, Slavin S, Reifers J, Gorin NC, Carella AM, Mandelli F, Burdach S, Ferrant A, Linkesch W, Tura S, Bacigalupo A, Schindel F, Heinrichs H: A controlled trial of human erythropoietin after bone marrow transplantation. Blood 1994, 84:3327-3335.
27. Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 1995, 86:419-431.
28. Basser R, Clarke K, Fox R, Green M, Cebon J, Marry J, Menchaca D, Tomita D, Begley G: Randomized, double-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMDGF) administered to patients with advanced cancer before and after chemotherapy: early results. Blood 1995, 86(suppl 1):257a.